Clarity Pharmaceuticals Ltd (ASX:CU6) said St Vincent's Hospital in Sydney will launch a phase 2 trial to compare its copper-based radiopharmaceutical diagnostic product, 64Cu-SAR-bis-PSMA, with the standard of care, gallium-based 68Ga-PSMA-11, according to a Monday filing with the Australian bourse.

The trial will enroll 50 patients and test the detection rates of the products for sites of prostate cancer recurrence based on positron emission tomography or computed tomography scans, the filing said.

Company shares fell nearly 10% in recent Monday trade.

Price (AUD): $6.43, Change: $-0.71, Percent Change: -9.94%